Pancytopenia associated with low-dose methotrexate therapy – case reports
Abstract
Background: Methotrexate has gained wide acceptance due to its efficacy in a variety of inflammatory rheumatological disorders. However, it has the potential to cause serious, life-threatening complications. Risk-factors that are important in the development of pancytopenia include advanced age, impared renal function, low folic acid levels, decreased serum albumin and concurrent ingestion of medications involved in folate metabolism. Patients and results of treatment: In this paper, three patients who developed pancytopenia while being treated with low-dose methotrexate over the past years are presented. Factors for the developement of pancytopenia in these patients were: impaired renal function (first patient), concurrent use of trimethoprim-sulfamethoxazole (second patient) and folic acid deficiency (third patient). Conclusions: With the increasing long-term use of methotrexate, it is important that patients should be monitored during treatment for haematological side-effects, as pancytopenia can be a late manifestation. Furthermore, more attention should be paid to risk factors predisposing hematological toxicity of methotrexate before commencing this drugDownloads
The Author transfers to the Publisher (Zdravniški vestnik/Slovenian Medical Journal) all economic copyrights following form Article 22 of the Slovene Copyright and Related Rights Act (ZASP), including the right of reproduction, the right of distribution, the rental right, the right of public performance, the right of public transmission, the right of public communication by means of phonograms and videograms, the right of public presentation, the right of broadcasting, the right of rebroadcasting, the right of secondary broadcasting, the right of communication to the public, the right of transformation, the right of audiovisual adaptation and all other rights of the author according to ZASP.
The aforementioned rights are transferred non-exclusively, for an unlimited number of editions, for the term of the statutory
The Author can make use of his work himself or transfer subjective rights to others only after 3 months from date of first publishing in the journal Zdravniški vestnik/Slovenian Medical Journal.
The Publisher (Zdravniški vestnik/Slovenian Medical Journal) has the right to transfer the rights, acquired parties without explicit consent of the Author.
The Author consents that the Article be published under the Creative Commons BY-NC 4.0 (attribution-non-commercial) or comparable licence.
